Updates are available Correction dated 2020-11-11
Click to view Correction: https://doi.org/10.1038/s41417-020-00251-y
-
Authors
Pruller, Johanna
Hofer, Isabella
Ganassi, Massimo http://orcid.org/0000-0003-3163-9707
Heher, Philipp
Ma, Michelle T. http://orcid.org/0000-0002-3349-7346
Zammit, Peter S. http://orcid.org/0000-0001-9562-3072
-
Funding
Funding for this research was provided by:
RCUK | Medical Research Council (MR/P023215/1, MR/S002472/1, MR/P023215/1)
Wellcome Trust (WT ‐203949/Z/16/Z)
- License Information
-
More Information
Article History
Received: 3 June 2020
Revised: 25 August 2020
Accepted: 2 September 2020
First Online: 25 September 2020
Change Date: 30 October 2020
Change Type: Update
Change Details: This Article was originally published with an incorrect title: "A modified human Myogenin promoter that is highly active in alveolar rhabdomyosarcoma" instead of "A human Myogenin promoter modified to be highly active in alveolar rhabdomyosarcoma drives an effective suicide gene therapy". This has now been corrected in both the PDF and HTML versions of the Article.
Change Date: 11 November 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41417-020-00251-y
Compliance with ethical standards
:
: The authors declare that they have no conflict of interest.
